Indivior Pharmaceuticals (INDV) Short term Debt (2021 - 2025)

Indivior Pharmaceuticals' Short term Debt history runs 5 years deep, the most recent figure standing at $29.0 million for Q4 2025.

• On a quarterly basis, Short term Debt rose 61.11% year-over-year to $29.0 million in Q4 2025; TTM through Dec 2025 was $29.0 million, a 61.11% increase from a year earlier, with the FY2025 full-year figure at $29.0 million, up 61.11% from the prior year.
• Short term Debt grew to $29.0 million in Q4 2025 per INDV's latest filing, from $18.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $29.0 million in Q4 2025 and bottomed at $3.0 million in Q4 2021.
• The 5-year median for Short term Debt is $18.0 million (2024), against an average of $13.8 million.
• Across the five-year window, Short term Debt changed 0.0% in 2022 and surged 500.0% in 2024, its largest moves.
• Year by year, Short term Debt stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023, then jumped by 500.0% to $18.0 million in 2024, then soared by 61.11% to $29.0 million in 2025.
• Per Business Quant, the three latest INDV Short term Debt figures stand at $29.0 million (Q4 2025), $18.0 million (Q3 2025), and $18.0 million (Q2 2025).